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Dlesions may reasonably be left alone because they are un-
likely to progress and are not likely to require subsequent
revascularization. These data may assist coronary surgeons
in a common clinical dilemma.
Wewould like to acknowledge the contribution of Miss Kristine
Teoh (National University Hospital, Singapore) in the original
conception of this study.References
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Dr Joseph F. Sabik (Cleveland, Ohio). Dr Smith, Dr Sundt,
members, and guests, in this paper by Dr Hayward and col-
leagues, they address whether coronary arteries with moderate
stenosis or nonischemia-producing lesions should be bypassed
routinely during coronary artery bypass surgery. They conclude,
as a result of the low rate of disease progression and low arterial
graft patency, that it may be best not to bypass routinely right
coronary arteries with moderate stenosis. They come to a very
different conclusion for left-sided coronary arteries. Because
the rate of disease progression is higher and the patency of arte-
rial grafts performed to left-sided coronary arteries with moder-
ate stenosis is excellent, they suggest that routinely bypassing
left-sided coronary arteries with only moderate lesions may be
appropriate.
This study is timely and important, especially in light of recent
findings from the interventional study, FAME. In FAME,
FFR-guided percutaneous coronary revascularization resulted in
a 25% decrease in the combined end points of death, myocardial
infarction, need for CABG, or repeat PCI. In other words,
stenting moderate, or nonischemia-producing coronary artery
stenosis, resulted in worse clinical outcomes. Might this also be
true for routinely grafting coronary arteries with only moderate
or nonischemia-producing lesions? I have 4 questions for Dr
Hayward.
Although knowing how grafting influences coronary artery ste-
nosis progression in moderate lesions is interesting and suggestive,
to decide whether to graft coronary arteries with moderate stenosis
requires clinical outcomes data. Did you follow the clinical events
in these patients and, if you did, do you know if grafting moderate
coronary artery lesions resulted in poorer long-term outcomes?
Also, did it matter whether the grafted coronary with a moderate
lesion was right or left sided?
Second question: You observed different rates of lesion progres-
sion in the right and left coronary artery systems; moderately ste-
nosed left-sided coronary arteries have a higher rate of disease
progression than moderately stenosed right coronary arteries. Do
you have an explanation for why disease progression is different
for right- and left-sided coronary arteries?
Third question: Grafting a moderately stenosed coronary artery
clearly resulted in greater lesion progression.Was the rate of lesion
progression different whether an artery or saphenous vein was
used as the bypass conduit?
And last, should we be using FFR guidance in determining
which lesions should be bypassed during coronary artery bypass
surgery? Thank you for the privilege of discussing this paper.
Dr Hayward. Thank you, Dr Sabik, for your comments and
questions. I agree. I think that the data from FAME in interven-
tional cardiology and another study, DEFER, which just looked
at moderate lesions, which we can come back to, are very timely
and in some ways can be extrapolated to this study.
To answer your 4 questions directly, if I have them correctly,
clinical outcome data—I didn’t include the clinical data in this be-
cause (1) we already had a lot of information (this was primarily
intended as a study of angiographic progression) and (2) because
these patients are part of the trial, we reported the mid-term results
at AATS a couple of years ago and we are now awaiting the full
10-year completion data, and I have tried not to overtrawl the trialery c January 2013
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Ddata too much, and the clinical outcome data of these patients
might relate to the overall trial data, because we know the graft
patencies and we know the progression of disease.
However, I can say that on the multivariate analysis, PNVD
overall is not related to the incidence of death, myocardial infarc-
tion, or requirement for revascularization. The hazard ratio for all
of those is in the range of .85 to .15 for those 3 end points. That’s
looking at all vessels. And if you look at moderate vessels, progres-
sion of moderate lesions is not associated on a multivariate analy-
sis with the hazard ratio of death, infarction, or revascularization.
What we haven’t done, however, is divide those moderate vessels
into grafted and ungrafted. The numbers are getting very small
there.
So I cannot answer your question whether grafting a moderate
lesion versus not grafting a moderate lesion will alter the end
points that we have. We do not have recurrent angina as an end
point in our trial, because the trial is limited to the very hard
data points of death, infarction, and requirement for revasculariza-
tion, so I cannot answer that question. But, I can say that those clin-
ical end points are not related significantly to whether you have
progressive or nonprogressive disease on your angiogram.
Dr Sabik. Why that might be is interesting, and as I read your
paper I waswondering: Is this a competing risk problem?Moderate
coronary lesions tend to be the culprit lesions, the lesions that
acutely thrombose and result in myocardial infarctions. Might
these patients be having events if these lesions are not grafted? I be-
lieve a good hard look at the clinical outcomes is necessary to de-
termine whether to graft coronary arteries with moderate stenosis.
Dr Hayward. The second question that you asked is why
should the progression of moderate right lesions be less than on
the left, and I think that’s obviously, if you like, the meaning of
this paper. I don’t have a hypothesis. I guess it may be that the path-
ophysiology of these is different. People have imputed the impact
of lipids and the atherosclerotic burden and also of shear stresses,
and in pathologic studies of autopsies and in, now, the coronary
computed tomographic studies, we know that the burden of coro-
nary disease is higher in the overall population in left-sided rather
than right-sided vessels, and it has been postulated that’s because
left-sided vessels have more shear stresses being related to the left
ventricle because they have a different flow pattern compared with
the right coronary.
So it is possible, I guess, that the modern secondary prevention,
particularly statins, both in their lipid modulatory and anti-inflam-
matory effects, may be exerting a different effect in the right cor-
onary versus the left coronary, because they can modulate the lipid
impact and the inflammatory impact—in other words, the athero-
sclerotic driver—but they can’t alter the shear stresses, which are
driven by the left ventricle essentially. That is the only reason I can
think of why over 20 years, advances in medical therapy might
have left us with these very stable right coronary lesions.
Dr Sabik. I was wondering if this finding is a result of the way
plaque burden was measured. Because increase in coronary ste-
nosis is a result of increase in plaque thickness, by measuring
percentage stenosis and not plaque thickness, I believe your find-
ings may be a result of the differences in the different coronaryThe Journal of Thoracic and Caartery diameters. A millimeter increase in plaque thickness will
have a much greater effect on the percentage stenosis of circum-
flex with a 2-mm diameter then it would on a right coronary
artery with a 5-mm diameter. To determine disease progression
accurately, it may be necessary to determine changes in plaque
size, not just percent stenosis.
Dr Hayward. That is a very good observation. We did not per-
form quantitative analysis, because to go back for 3800 vessels and
perform quantitative analysis would be an enormous task, and we
don’t have funding for the team of people that would be needed to
do that. But I think for these moderate lesions, particularly the un-
grafted moderate lesions, the number is much smaller, and I think
we should go back and do exactly that analysis—do quantitative
analysis—to measure the burden of disease and find out whether
this is, as you say, truly a stability effect of medical therapy or is
it actually an artifact of a bigger vessel. It takes more burden to ste-
nose a bigger vessel. I suspect the former is true, but we can mea-
sure that.
In terms of your third question, which was choice of conduit,
there is no difference in the disease progression on multivariate
analysis between whether you place an arterial or a vein graft,
and that data will be in the manuscript with all the complete
data. But, choice of conduit does not seem to impact on the rate
of progression.
Your fourth question, I think, is whether the use of FFR should
guide these studies, and I think that is the key point. Some of those
moderate lesions are flow limiting; some of them are not. We know
from the DEFER study, which was a study in interventional cardi-
ology of 50% to 70% stenoses, and they performed FFR on those,
only one-third of those lesions had an FFR of<0.75—in other
words, were flow limiting—and the ones that weren’t, they then
randomized to stent or medical management. Not surprisingly,
those patients who got medical management did significantly bet-
ter than those who got a stent. And I think surgeons would recog-
nize that if you put a stent in a vessel that is not actually flow
limiting, that is going to impact on your long-term outcome, be-
cause it represents a lifetime risk for you.
We probably feel that the same is not true of bypass surgery, be-
cause if you put a bypass graft to a vessel and it wasn’t actually
flow limiting, well, the worst that can happen is the graft will
fail and you haven’t done any harm.
And I think what is interesting in our data is that may not be
true, that the findings of FAME and DEFERmight relate to surgery
as well. Putting a bypass to a vessel that doesn’t need it might be a
bad thing, but if you accelerate the disease progression, especially
as you probably put a vein graft to the right coronary—because
you and other authors have documented the worst outcome of ar-
terial grafts on moderate right lesions—if you are going to put
a vein graft, you may accelerate the progression of the native dis-
ease, and that patient then becomes dependent on a graft on the
right side, and that graft is going to have an attrition. So I think
FFR to guide the actual revascularization of these lesions in the
future will be the way to go.
Dr Sabik. Thank you, and congratulations on an excellent
presentation and paper.rdiovascular Surgery c Volume 145, Number 1 149
